Remembering Jay Nelson
OHSU and the world have lost a great scientist and leader. Jay A. Nelson, Ph.D., founding director of the Vaccine & Gene Therapy Institute, passed away after a long illness. A virologist with many scientific interests, Jay focused considerable attention on the herpes family of viruses, especially on cytomegalovirus, or CMV. He and his team carried out molecular analyses of human CMV replication and pathogenesis, determined molecular mechanisms of CMV latency, and were among the first to characterize microRNAs (miRNAs) produced during CMV infection. He was highly prolific, with many papers in the best journals, and he had an outstanding track record in obtaining grants for his lab and for large collaborative projects. Continue reading
About us
The Vaccine and Gene Therapy Institute at Oregon Health & Science University has assembled a multidisciplinary team of scientists to respond to serious viral disease threats, including AIDS, chronic viral infection-associated diseases, newly emerging viral diseases and infectious diseases of the elderly. Our programs are intended to span the continuum between basic and clinical science, in which discoveries are rapidly advanced from the level of molecular and cellular biology through animal models and ultimately into clinical testing. Learn more
Upcoming seminars
VGTI Seminar Series and Virology Journal Club is now streamed online. Please reach out to Chad (sixkille@ohsu.edu) if you would like a link to the live stream. Only available internally to OHSU.
Recent publications
J Virol. March 19, 2024
Correction for Rasmussen et al., "Virology-the path forward"
bioRxiv Feb 28, 2024
Rhesus Cytomegalovirus-encoded Fcγ-binding glycoproteins facilitate viral evasion from IgG-mediated humoral immunity
bioRxiv Feb 28, 2024
Pre-challenge gut microbial signature predicts RhCMV/SIV vaccine efficacy in rhesus macaques
Viruses Feb 15, 2024
SIV Infection Is Associated with Transient Acute-Phase Steatosis in Hepatocytes In Vivo
Viruses Feb 1, 2024
High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5
J Virol. Jan 23, 2024
Virology-the path forward
Donate to VGTI
Your gifts help provide vital resources to conduct innovative research and more.
COVID-19 Efforts - Building a COVID Testing Lab